Fig. 7

Combination study of sv6D and anti-PD-1. a The design of the experiment and extension of survival of C57BL/6 female mice implanted with ovarian cancer cell line ID8 and treatments with anti-PD-1 and sv6D. Anti-PD-1 (rat anti-mouse, clone 29F.1A12) was administered intraperitoneally every other day, 200 μg protein per dose, between day 41 and 49 (red bars). sv6D was administered subcutaneously every other day at 0.1 nmole/g, starting on day 36, 51 or 87 (green bars). Survival data were analyzed by the Mantel-Cox log-rank test to determine ρ values. b Kaplan-Meier survival curves of mice treated with anti-PD-1 and/or sv6D. The figure shows survival of groups 1, 3, 6 and 8. For group 3, the Mantel-Cox log-rank test p = 0.003 indicates the significance between treatment with the combination and antibody alone. Anti-PD-1, green; sv6D, brown; anti-PD-1 followed by sv6D (Group 3 in a), red; PBS, black